TITLE

BIOCRYST/GREEN CROSS TO DEVELOP PERAMIVIR IN SOUTH KOREA

PUB. DATE
July 2006
SOURCE
Worldwide Biotech;Jul2006, Vol. 18 Issue 7, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on agreement between BioCryst Pharmaceuticals Inc. and Green Cross Corporation for the development and commercialization in Korea of peramivir, BioCryst's potent influenza neuraminidase inhibitor. Terms of the agreement; Potential of the deal according to Charles E. Bugg, chairman and CEO of BioCryst; Significance of the agreement to the operations of BioCryst.
ACCESSION #
21352200

 

Related Articles

  • Global diseases.  // MLO: Medical Laboratory Observer;Jan2007, Vol. 39 Issue 1, p8 

    The article reports on the development of a drug by U.S.-based BioCryst Pharmaceuticals which has been shown to have the potential frontline treatment for avian flu virus. According to a report, the drug is in Phase II trials and should be approved within two to three years in the U.S. Moreover,...

  • BioCryst's Peramivir as Good as Tamiflu.  // Bioworld Week;7/27/2009, Vol. 17 Issue 30, p2 

    The article reports on the result of the Phase III study of the seasonal flu drug peramivir from BioCryst Pharmaceuticals Inc., which proved noninferior to Tamiflu. It notes that the result has encouraged investors for a government stockpiling contract to deal with the invasive threat of swine...

  • BIOCRYST INITIATES INTRAVENOUS PHASE I/II OF FODOSINE.  // Biotech Business;Feb2006, Vol. 19 Issue 2, p6 

    No abstract available.

  • MANUFACTURERS INDEX.  // Monthly Prescribing Reference;Feb2016, Vol. 32 Issue 2, p304 

    A drug manufacturers index for the February 2016 issue of "Monthly Prescribing Reference" journal is presented.

  • BioCryst Monetizes Peramivir Payments in $30M Financing.  // Bioworld Week;3/14/2011, Vol. 19 Issue 11, p5 

    The article offers information on the license agreement between BioCryst Pharmaceuticals Inc. and Shionogi & Co. Ltd. for peramivir (Rapiacta), drug used to treat influenza.

  • CLINIC ROUNDUP.  // BioWorld Today;6/19/2007, Vol. 18 Issue 118, p9 

    This section presents news briefs concerning the U.S. pharmaceutical industry. Results from two Phase 1 trials of an intramuscular formulation of peramivir was presented by BioCryst Pharmaceuticals Inc. at a conference in Toronto, Ontario. The results for two studies was announced by Genzyme...

  • FINANCINGS.  // BioWorld Today;8/1/2013, Vol. 24 Issue 146, p10 

    The article reports on the plan of Biocryst Pharmaceuticals Inc. to sell about 20 million U.S. dollars in gross proceeds in an underwritten public offering in 2013.

  • Peramivir Stumbles In Phase II Influenza Study.  // Bioworld Week;9/24/2007, Vol. 15 Issue 39, p5 

    The article reports on the performance of the stocks of BioCryst Pharmaceuticals Inc. in the U.S. The shares of BioCryst tumbled more than 30% following a Phase II trial miss with the influenza drug peramivir. The firm's stock, which traded at 18 times the normal volume, fell $3.78 or 32% to...

  • BioCryst Getting $14M Up Front From Japanese Peramivir Partner. Boggs, Jennifer // BioWorld Today;2/7/2007, Vol. 18 Issue 45, p1 

    The article reports that BioCryst Pharmaceuticals Inc. has licensed Japanese rights to the influenza antiviral peramivir in a potential $130 million deal. The deal includes a $14 million up-front payment from Osaka, Japan-based Shionogi & Co. Ltd., which receives rights in Japan to create...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics